BRCA1 and neoplasm: Of these, 23 patients were confirmed germline BRCA1/2 mutation carriers (gBRCA1/2); however, two of these patients could not be evaluated with regard to antitumour response due to toxicity and stopping the drug after less than 4 weeks, while another two had tumours not typically associated with BRCA carrier status: one with small-cell lung cancer and one with vaginal adenocarcinoma.